Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.
Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list.
Company Details
- Employees
- 46
- Founded
- -
- Address
- Lunastigen 5, Box 1086,sweden
- Phone
- +46 (0)85-468-3100
- in****@****vir.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- medivir.com
- HQ
- Huddinge
Medivir Ab Questions
Medivir Ab's helpline number is +46 (0)85-468-3100
Medivir Ab's website is medivir.com
Medivir Ab's LinkedIn profile is https://se.linkedin.com/company/medivir
Medivir Ab has
46 employees.
View email and phone details for 46
employees at Medivir Ab.
Medivir Ab's industry is
Pharmaceutical Manufacturing
Medivir Ab's top competitors are
Sprint Bioscience,
Sedana Medical,
Xbrane Biopharma Ab,
Alzecure Pharma,
Kancera,
Northx Biologics,
Bioarctic,
Oncopeptides Ab (Publ),
Sobi - Swedish Orphan Biovitrum Ab (Publ),
Calliditas Therapeutics.
Medivir Ab's support email address is info@medivir.com
Medivir Ab's categories are Pharmaceutical Manufacturing
Medivir Ab's founding year is 1988
